Our director, Prof. Liesbet Geris attended the event and contributed to the session on “Resilience and Reliability: Securing Rare Disease Diagnosis and Care in a Changing World" bringing the in silico medicine perspective to the discussion.
The proposed MDR revision marks a turning point for our community, explicitly recognising in silico modelling & simulation as a source of evidence in EU medical device guidance.
In November 2025, the European Innovation Council (EIC) launched a new Pathfinder Challenge on Biotechnology for Healthy Ageing under the EIC Work Programme 2026.
The European Commission has published the Horizon Europe Work Programme for 2026 and 2027, setting out the next wave of research and innovation funding under the EU’s flagship programme. The overall programme allocates €14 billion to strategic research and innovation priorities across multiple clusters, including health, digital, industry, climate and more.
The European Commission has welcomed a political agreement reached by the European Parliament and the Council to modernise the EU pharmaceutical legislation — the most significant overhaul in over 20 years.
As 2025 closes, we celebrate VPH’s progress and look to 2026 as a year of consolidation, with in silico medicine recognised in key EU policies and VPH2026 Conference ahead in Milan.
How hybrid AI models, grounded in physics, enable explainability and trustworthy prediction, at lightning speed.
